Predictivity of in vitro non-clinical cardiac contractility assays for inotropic effects in humans - A literature search

Journal of Pharmacological and Toxicological Methods

Volumn 75, Issue , 2015, Pages 62-69

  Wallis, Rob ^a   Gharanei, Mayel ^a,b   Maddock, Helen ^a,b  

^a InoCardia Ltd Technocentre   (United Kingdom)

^b Faculty of Health and Life Sciences   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; ATENOLOL; CAPTOPRIL; CIBENZOLINE; CLONIDINE; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOBUTAMINE; ENOXIMONE; FLECAINIDE; GLIBENCLAMIDE; INOTROPIC AGENT; ITRACONAZOLE; LEVOSIMENDAN; METOPROLOL; MILRINONE; NIFEDIPINE; PHENTOLAMINE; PHENYLEPHRINE; PIMOBENDAN; SUNITINIB; VERAPAMIL;

ADVERSE DRUG REACTION; ASSAY; BIOMECHANICS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART ATRIUM; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HEART RATE; HEART VENTRICLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; IMPEDANCE; IN VITRO STUDY; IN VIVO STUDY; INOTROPISM; ISCHEMIC HEART DISEASE; ISOLATED HEART; KIDNEY CARCINOMA; MUSCLE ISOMETRIC CONTRACTION; MUSCLE ISOTONIC CONTRACTION; NON CLINICAL CARDIAC CONTRACTILITY ASSAY; NONHUMAN; PREDICTION; REVIEW; RHEUMATIC HEART DISEASE; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYMPTOM; VASCULAR RESISTANCE; ANIMAL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART; HEART CONTRACTION; PROCEDURES; SPECIES DIFFERENCE; TOXICITY TESTING;

ANIMALS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART; HUMANS; MYOCARDIAL CONTRACTION; SENSITIVITY AND SPECIFICITY; SPECIES SPECIFICITY; TOXICITY TESTS;

EID: 84942551329     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2015.05.009     Document Type: Review

References (110)

1. Adeyemi O., Roberts S., Harris J., West H., Shome S. QA interval as an indirect measure of cardiac contractility in the conscious telemeterised rat: Model optimization and evaluation. Journal of Pharmacological and Toxicological Methods 2009, 60(2):159-166.
2. Ahmad S.R., Singer S.J., Leissa B. Congestive heart failure associated with itraconazole. Lancet 2001, 357:1766-1767.
3. Anning P.B., Grocott-Mason R.M., Lewis M.J., Shah A.M. Enhancement of left ventricular relaxation in the isolated heart by an angiotensin-converting enzyme inhibitor. Circulation 1995, 92:2660-2665.
4. Antila S., Eha J., Heinpalu M., Lehtonen L., Loogna I., Mesikepp A., et al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. European Journal of Clinical Pharmacology 1995, 49:451-458.
5. Arrowsmith J., Miller P. Phase II and phase III attrition rates 2011-2012. Nature Reviews Drug Discovery 2013, 12:569.
6. Baruch L., Patacsil P., Hameed A., Pina I., Loh E. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. American Heart Journal 2000, 141(2):266-273.
7. Bell R.M., Mocanu M.M., Yellon D.M. Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion. Journal of Molecular and Cellular Cardiology 2011, Jun, 50(6):940-950.
8. Belz G.G., Meinicke T., Schäfer-Korting M. The relationship between pharmacokinetics and pharmacodynamics of enoximone in healthy man. European Journal of Clinical Pharmacology 1988, 35:631-635.
9. Blasi E., Heyen J., Patyna S., Hemkens M., Ramirez D., John-Baptiste A., et al. Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function. Cardiovascular Therapeutics 2012, 30:287-294.
10. Boknik P., Neumann J., Kaspareit G., Schmitz W., Scholz H., Vahlensieck U., et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. Journal of Pharmacology & Experimental Therapeutics 1997, 280(1):277-283.
11. Boudot J.P., Cavero I., Roach A.G. Cardiovascular effects of diltiazem, a calcium antagonist, on isolated heart muscle preparations and in anaesthetized and pithed rats. Proceedings of British Pharmacology Society 1978, (403P).
12. Bourassa M.G., Cote P., Theroux P., Tubau J.F., Genain C., Waters D.D. Hemodynamics and coronary flow following diltiazem administration in anesthetized dogs and in humans. Chest 1980, 78:224-230.
13. Brown L., Erdmann E. Concentration-response curves for positive inotropic agents before and after ouabain pretreatment. Cardiovascular Research 1985, 19(5):288-298.
14. Brunkhorst D., v.der Leyen H., Meyer W., Nigbur R., Scmidt-Schumaker C., Scholz H. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart. Naunyn-Schmiedeberg's Archives of Pharmacology 1989, 339:575-583.
15. Caiozzo V.J. Plasticity of skeletal muscle phenotype: Mechanical consequences. Muscle and Nerve 2002, 26:740-768.
16. Cambridge D., Whiting M. Evaluation of the QA interval as an index of cardiac contractility in anaesthetised dogs: Responses to change in cardiac loading and heart rate. Cardiovascular Research 1986, 20(6):444-450.
17. Cavero I., Roach A.G. Effects of clonidine on canine cardiac neuroeffector structures controlling heart rate. British Journal of Pharmacology 1980, 70(2):269-276.
18. Chu K.-M., Hu O.Y.-P., Shieh S.-M. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamics modeling of pimobendan in healthy normal subjects. American Society for Pharmacology and Experimental Therapeutics 1999, 27(6):701-709.
19. Cook D., Brown D., Alexander R., March R., Morgan P., Satterthwaite G., et al. Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nature Reviews Drug Discovery 2014, 13:419-431.
20. Di Lorenzo G., Autorino R., Bruni G., Cartenì G., Ricevuto E., Tudini M. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Annals of Oncology 2009, 20:1535-1542.
21. Doherty K.R., Wappel R.L., Talbert D.R., Trusk P.B., Moran D.M., Kramer J.W., et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicology and Applied Pharmacology 2013, 272(1):245-255.
22. Edelson J., LeJemtel T.H., Alousi A.A., Biddlecome C.E., Maskin C.S., Sonnenblick E.H. Relationship between amrinone plasma concentration and cardiac index. Clinical Pharmacology and Therapeutics 1981, 29(6):723-728.
23. Eichelbaum M., Birkel P., Grube E., Gütgemann U., Somogyi A. Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klinische Wochenschrift 1980, 58:919-925.
24. Ertl R., Jahnel U., Nawrath H., Carmeliet E., Vereecke J. Differential electrophysiologic and inotropic effects of phenylephrine in atrial and ventricular heart muscle preparations from rats. Naunyn-Schmiedeberg's Archives of Pharmacology 1991, 344:574-581.
25. Franco-Cereceda A., Lundberg J.M. Calcitonin gene-related peptide (CGRP) and capsaicin-induced stimulation of heart contractile rate and force. Naunyn-Schmiedeberg's Archives of Pharmacology 1985, 331(2-3):146-151.
26. Fujino K., Sperelakis N., Solaro J. Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: Comparison with milrinone. Circulation Research 1988, 63:911-922.
27. Gharanei M., Hussain A., James R.S., Janneh O., Maddock H. Investigation into the cardiotoxic effects of doxorubicin on contractile function and the protection afforded by cyclosporin A using the work-loop assay. Toxicology In Vitro 2014, 28:722-731.
28. Gharanei M., Hussain A., Janneh O., Maddock H.L. Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore. Toxicology and Applied Pharmacology 2012, 268(2):149-156.
29. Grant A.O., Hondeghem L.M., Katzung B.G. Effects of droperidol on depolarization-induced automaticity, maximum upstroke velocity (Vmax) and the kinetics of recovery of Vmax in guinea-pig ventricular myocardium. Journal of Pharmacology and Experimental Therapeutics 1978, 205(1):193-203.
30. Guo L., Abrams R.M., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., et al. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicological Sciences 2011, Sep, 123(1):281-289.
31. Haglund K., Collste P. Time course of blood pressure, pulse rate, plasma renin and metoprolol treatment. European Journal of Clinical Pharmacology 1980, 17:321-328.
32. Hamlin R.L., del Rio C. dP/dtmax - A measure of 'baroinometry'. Journal of Pharmacological and Toxicological Methods 2012, 66:63-65.
33. Hansen P.B., Buch J., Rasmussen O.Ø., Waldorff S., Steiness E. Influence of atenolol and nifedipine on digoxin-induced inotropism in humans. British Journal of Clinical Pharmacology 1984, 18:817-822.
34. Harding S.E., Ali N.N., Brito-Martins M., Gorelik J. The human embryonic stem cell-derived cardiomyocyte as a pharmacological model. Pharmacology & Therapeutics 2007, 113(2):341-353.
35. Harmer A.R., Abi-Gerges N., Morton M.J., Pullen G.F., Valentin J.P., Pollard C.E. Validation of an in vitro contractility assay using canine ventricular myocytes. Toxicology and Applied Pharmacology 2012, 260(2):162-172.
36. Hermiller J.B., Magorien R.D., Leithe M.E., Unverferth D.V., Leier C.V. Clonidine in congestive heart failure: A vasodilator with negative inotropic effects. American Journal of Cardiology 1983, 51(5):791-795.
37. Hill R.E., Heard K., Bogdan G.M., Cairns C.B., Dart R.C. Attenuation of verapamil-induced myocardial toxicity in an ex-vivo rat model using a verapamil-specific ovine immunoglobin. Academic Emergency Medicine 2001, 8(10):950-955.
38. Himmel H.M. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds. Journal of Pharmacological and Toxicological Methods 2013, 68(1):97-111.
39. Hirakawa S., Sasayama S., Tomoike H., Crozatier B., Franklin D., Mckown D., et al. In situ measurement of papillary muscle dynamics in the dog left ventricle. American Journal of Physiology 1977, 233:H384-H391.
40. Holck M., Osterrieder W. Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline. British Journal of Pharmacology 1986, 87:705-711.
41. Holtzman J.L., Finley D., Mottonen L., Berry D.A., Elcholm B.P., Kvam D.C., et al. The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: Effects on cardiac function and drug clearance. Clinical Pharmacology and Therapeutics 1989, 46:26-32.
42. Honerjäger P., Loibl E., Steidl I., Schönsteiner G., Ulm K. Negative inotropic effects of tetrodotoxin and seven class I antiarrhythmic drugs in relation to sodium channel blockade. Naunyn-Schmiedeberg's Archives of Pharmacology 1986, 332:184-195.
43. Houk B.E., bello C.L., Kang D. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clinical Cancer Research 2009, 15:2497-2506.
44. Huizer T., Van Der Meer P., De Jong J.W. Captopril inhibits angiotensin I-induced coronary flow reduction in isolated rat heart but has no effect on contractility or energy metabolism. European Heart Journal 1992, 13(1):109-114.
45. ICH S7A International conference on harmonization. Safety pharmacology studies for human pharmaceuticals S7A 2000.
46. Ito K., Nagafuchi K., Taga A., Yorikane R., Koike H. Possible involvement of altered Na+-Ca2+ exchange in negative inotropic effects of class I antiarrhythmic drugs on rabbit and rat ventricles. Journal of Cardiovascular Pharmacology 1996, 27(3):355-361.
47. James R.S., Young I.S., Cox V.M., Goldspink D.F., Altringham J.D. Isometric and isotonic muscle properties as determinants of work loop power output. Pflügers Archiv 1996, 432:767-774.
48. Josephson R.K. Mechanical power output from striated muscle during cyclic contraction. Journal of Experimental Biology 1985, 493-512.
49. Josephson R.K. Contraction dynamics and power output of skeletal muscle. Annual Review of Physiology 1993, 55:527-546.
50. Khan J.M., Lyon A.R., Harding S.E. The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening. British Journal of Pharmacology 2013, 169(2):304-317.
51. Khatib S.Y., Boyett M.R. Effects of glyburide (glibenclamide) on myocardial function in Langendorff perfused rabbit heart and on myocardial contractility and slow calcium current in guinea-pig single myocytes. Molecular and Cellular Biochemistry 2003, 242:81-87.
52. Kondo N., Mizukami M., Shibata S. Negative inotropic effects of disopyramide on guinea-pig papillary muscles. British Journal of Pharmacology 1990, 101:789-792.
53. Kraushaar U., Meyer T., Hess D., Gepstein L., Mummery C.L., Braam S.R., et al. Cardiac safety pharmacology: From human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models. Expert Opinion on Drug Safety 2012, 11(2):285-298.
54. Landzberg J.S., Parker J.D., Gauthier D.F., Colucci W.S. Effects of myocardial α1-adrenergic receptor stimulation and blockade on contractility in humans. Circulation 1991, 84:1608-1614.
55. Layland J., Kentish J.C. Positive force- and [Ca2+]i-frequency relationships in rat ventricular trabeculae at physiological frequencies. American Journal of Physiology 1999, 276:H9-H18.
56. Layland J., Kentish J.C. Effects of 1- or -adrenoceptor stimulation on work-loop and isometric contractions of isolated rat cardiac trabeculae. Journal of Physiology 2000, 524(Pt 1):205-219.
57. Layland J., Young I.S., Altringham J.D. The length dependence of work production in rat papillary muscles in vitro. Journal of Experimental Biology 1995, 198:2491-2499.
58. Lee Y.K., Ng K.M., Lai W.H., Chan Y.C., Lau Y.M., Lian Q., et al. Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Reviews 2011, 7(4):976-986.
59. Lewis R.V., Lennard M.S., Jackson P.R., Tucker G.T., Ramsay L.E., Woods H.F. Timolol and atenolol: Relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology 1985, 19:329-333.
60. Liljedahl S., Kahan T., Lind L., Ärnlöv J. The effects of antihypertensive treatment on the Doppler-derived myocardial index in patients with hypertensive left ventricular hypertrophy: Results from the Swedish Irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA). Echocardiology: A Journal of Cardiovascular Ultrasound and Allied Technology 2009, 26(7):753-758.
61. Lilleberg J., Sundberg S., Häyhä M., Akkila J., Nieminen M.S. Haemodynamic dose-efficacy of Levosimendan in healthy volunteers. European Journal Clinical Pharmacology 1994, 47:267-274.
62. Lu C., Carlino M., Fragasso G., Maisano F., margonato A., Cappelletti A., et al. Enoximone echocardiography for predicting recovery of left ventricular dysfunction after revascularisation. A novel test for detecting myocardial viability. Circulation 2000, 101:1255-1260.
63. Lüllman H., Ravens U. The time courses of the changes in contractile force and in transmembrane potentials induced by cardiac glycosides in the guinea-pig papillary muscle. British Journal of Pharmacology 1973, 49:377-390.
64. Lumley P., Broadley K.J., Levy G.P. Analysis of the inotropic:chronotropic selectivity of dobutamine and dopamine in anaesthetised dogs and guinea-pig isolated atria. Cardiovascular Research 1977, 11:17-25.
65. Marcovitz P.A., Armstrong W.F. Impact of metoprolol on heart rate, blood pressure, and contractility in normal subjects during dobutamine stress echocardiography. American Journal of Cardiology 1997, 80:386-388.
66. Markert M., Klumpp A., Trautmann T., Mayer K., Stubhan M., Guth B. The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates. Journal of Pharmacological and Toxicological Methods 2007, 56(2):203-211.
67. Matsui K., Kiyosue T., Wang J.-C., Dohi K., Arita M. Effects of pimobendan on the L-type Ca2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: Comparison with IBMX, milrinone, and cilostazol. Cardiovascular Drugs and Therapy 1999, 13(2):105-113.
68. Matsuoka S., Nawada T., Hisatome I., Miyamoto J., Hasegawa J., Kotake H., et al. Comparison of Ca2+ channel inhibitory effects of cibenzoline with verapamil on guinea-pig heart. General Pharmacology: The Vascular System 1991, 22(1):87-91.
69. Mellors L.J., Barclay C.J. The energetics of rat papillary muscles undergoing realistic strain patterns. Journal of Experimental Biology 2001, 204:3765-3777.
70. Mellors L.J., Gibbs C.L., Barclay C.J. Comparison of the efficiency of rat papillary muscles during after loaded isotonic contractions and contractions with sinusoidal length changes. Journal of Experimental Biology 2001, 204:1765-1774.
71. Miller R.R., Vismara L.A., Zelis R., Amsterdam E.A., Mason D.T. Clinical use of d sodium nitroprusside in chronic ischemic heart disease. Effects on peripheral vascular resistance and venous tone and on ventricular volume, pump and mechanical performance. Circulation 1975, 51:328-336.
72. Miller J.S., Williams V. Effects on rabbit nodal, atria, ventricular, and Purkinje cell potential of the new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. British Journal of Pharmacology 1982, 75:469-478.
73. Mitchell A., Bührmann S., Saez A.O., Rushentsova U., Schäfers R.F., Philipp T., et al. Clonidine lowers blood pressure by reducing vascular resistance and cardiac output in young, healthy males. Cardiovascular Drugs and Therapy 2005, 19:49-55.
74. Montaigne D., Marechal X., Preau S., Baccouch R., Modine T., Fayad G., et al. Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion 2011, 11:22-26.
75. Motomura S., Brodde O.E., Schümann H.J. No evidence for involvement of dopaminergic receptors in the positive inotropic action of dopamine on the isolated rabbit papillary muscle. Japanese Journal of Pharmacology 1978, 28:145-153.
76. Noguchi K., Takahashi K., Higuchi S. In-vitro negative chronotropic and inotropic effects of a novel dihydropyridine derivative, CD-832, in the guinea-pig: Comparison with calcium-channel antagonists. Journal of Pharmacy and Pharmacology 1998, 50(3):329-334.
77. Naruto K., Iacono G., Vezina M. Assessment of the pharmacological effects of inotropic drugs on left ventricular pressure and contractility: An evaluation of the QA interval as an indirect indicator of cardiac ionotropism. Journal of Pharmacological and Toxicological Methods 2009, 60(2):193-197.
78. Orphanos G.S., Ioannidis G.N., Ardavanis A.G. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncologica 2009, 48:964-970.
79. Packer M., Medina N., Yushak M. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe heart failure. Circulation 1984, 70(6):1038-1047.
80. Packer, et al. Effect of oral milrinone on mortality in chronic heart failure. New England Journal of Medicine 1991, 325:1468-1475.
81. Pollick C., Giacomini K.M., Blaschke T.F., Nelson W.L., Turner-Tamiyasu K., Briskin V., et al. The cardiac effects of d- and l-disopyramide in normal subjects: A noninvasive study. Circulation 1982, 66:447-453.
82. Qu Y., Fang M., Gao B., Amouzadeh H.R., Li N., Narayanan P., et al. Itraconazole decreases left ventricular contractility in isolated rabbit heart: Mechanism of action. Toxicology and Applied Pharmacology 2013, 268:113-122.
83. Riou B., Lecarpentier Y., Viars P. Inotropic effect of ketamine on rat cardiac papillary muscle. Anesthesiology 1989, 71:116-125.
84. Rothschild M.A., Rothschild A.H., Pfeifer M.A. The inotropic action of tolbutamide and glyburide. Clinical Pharmacology and Therapeutics 1989, 45:642-649.
85. Rump A.F., Acar D., Klaus W. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. British Journal of Pharmacology 1994, 112(3):757-762.
86. Sanchez-Chapula J. Multiple effects of putative α-adrenoceptor agonists on the electrical and mechanical activity of guinea-pig papillary muscle. Naunyn-Schmiedeberg's Archives of Pharmacology 1981, 316:108-111.
87. Sartor G., Melander A., Scherstén B., Wåhlin-Boll E. Serum glibenclamide in diabetic patients, and influence of food on the kinetics of glibenclamide. Diabetologia 1980, 18:17-22.
88. Sato K., Kandori H., Sato S. Evaluation of a new method using telemetry for monitoring the left ventricular pressure in free-moving rats. Journal of Pharmacological and Toxicological Methods 1994, 31(4):191-198.
89. Sato S., Talukder M.A., Sugawara H., Sawada H., Endoh M. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. Journal of Molecular and Cellular Cardiology 1998, 30(6):1115-1128.
90. Schulz M., Schmodt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 2003, 58:447-474.
91. Scott C.W., Zhang X., Abi-Gerges N., Lamore S.D., Abassi Y.A., Peters M.F. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Toxicol Sci 2014, 142:331-338.
92. Seals A.A., Haider R., Leon C., Francis M., Young J.B., Roberts R., et al. Antiarrhythmic efficacy and hemodynamic effects of cibenzoline in patients with nonsustained ventricular tachycardia and left ventricular dysfunction. Circulation 1987, 75(4):800-808.
93. Semafuko W.E., Bowie W.C. Papillary muscle dynamics: In situ function and responses of the papillary muscle. American Journal of Physiology 1975, 228:1800-1807.
94. Shaid M., Rodger I.W. Chronotropic and inotropic actions of milrinone, carbazeran and isobutylmethyl xanthine: Role of phosphodiesterase inhibition. British Journal of Pharmacology 1989, 98:291-301.
95. Shaw T.R.D., Duncan F.M., Williams B.C., Crichton E., Thomson S.A., Davis J.R.E., et al. Plasma free captopril concentrations during short and long term treatment with oral captopril for heart failure. British Heart Journal 1985, 54:160-165.
96. Shiels H.A., White E. The Frank-Starling mechanism in vertebrate cardiac myocytes. Journal of Experimental Biology 2008, 211:2005-2013.
97. Siegel P.K.S., Morgan G., Sweet C.S. Responses to amrinone in isolated cardiac muscles from cat, rabbit and guinea pig. Journal of Cardiovascular Pharmacology 1984, 6:281-287.
98. Singh B.N., Phil F.R.A.C.P., Roche A.H.G. Effects of intravenous verapamil on hemodynamics in patients with heart disease. American Heart Journal 1977, 94(5):593-599.
99. Skrzypiec-Spring M., Grotthus B., Szelag A., Schulz R. Isolated heart perfusion according to Langendorff - Still viable in the new millennium. Journal of Pharmacological and Toxicological Methods 2007, 55(2):113-126.
100. Sperelakis N. Heart physiology and pathophysiology 2001, Academic Press, San Diego, Calif.
101. Suga H., Sagawa K., Shoukas A.A. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circulation Research 1973, 32(3):314-322.
102. Sundberg S., Antila S., Scheinin H., Häyhä M., Virtanen M., Lehtonen L. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. International Journal of Clinical Pharmacology and Therapeutics 1998, 36(12):629-635.
103. Syme D.A., Josephson R.K. Influence of muscle length on work from trabecular muscle of frog atrium and ventricle. Journal of Experimental Biology 1995, 198:2221-2227.
104. Tuttle R.R., Mills J. Dobutamine: Development of a new catecholamine to selectively increase cardiac contractility. Circulation Research 1975, 36:185-196.
105. Varma D.R., Shen H., Deng X.F., Peri K.G., Chemtob S., Mulay S. Inverse agonist activities of b-adrenoceptor antagonists in rat myocardium. British Journal of Pharmacology 1999, 127:895-902.
106. Véniant M., Clozel J.-P., Hess P., Wolfgang R. Ro-40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. Journal of Cardiovascular Research 1991, 17:277-284.
107. Williams J.F., Mathew B. Effect of quinidine on positive inotropic action of digoxin. American Journal of Cardiology 1981, 47(5):1052-1055.
108. Wing L.M.H., Reid J.L., Davies E.A.M., Tippett N.P., Dollery C.T. Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. European Journal of Clinical Pharmacology 1997, 12:463-469.
109. Zausig Y.A., Stowe D.F., Zink W., Grube C., Martin E., Graf B.M. A comparison of three phosphodiesterase type II inhibitors on mechanical and metabolic function in the guinea pig isolated hearts. Anesthesia and Analgesia 2006, 102:1646-1652.
110. Zimpfer M., Vatner S.F. Effects of acute increases in left ventricular preload and indices of myocardial function in conscious, unrestrained and intact, tranquilized baboons. Journal of Clinical Investigation 1981, 67(2):430-438.